A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

Trial Details

NCT ID
NCT07284758
Phase
PHASE2
Sponsor
C4 Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Cemsidomide
  • Dexamethasone
Locations (sample)
  • West Hollywood, California, United States|34.09001,-118.36174
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Be willing and able to provide signed informed consent for the study.
  • Age ≥ 18 years at the time of signed consent.
  • Subjects must have a documented diagnosis of MM and measurable disease at enrollment.
  • Received at least 3 prior anti-myeloma regimens (for a minimum of 2 or more consecutive cycles) that must have included an immunomodulatory drug (i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →